Joy Liu Biography and Net Worth

Joy Liu joined Vertex in 2016 and is Senior Vice President and General Counsel. She serves on the company’s Executive Committee and oversees all aspects of the Legal and Office of Business Integrity and Ethics functions. Prior to assuming her current role in 2021, Ms. Liu held multiple leadership positions within the Legal team, most recently as Senior Vice President and Deputy General Counsel. She has deep experience providing legal, regulatory, privacy and business contracting counsel to a broad range of global functions across the company.

Ms. Liu joined Vertex from Ropes and Gray LLP, where she practiced FDA regulatory law for 14 years, including five as partner. While at the firm, she worked on a number of high-profile cases, defending her clients and successfully challenging decades-old FDA policies and guidance. Ms. Liu has advised on a broad range of matters, including regulatory approval strategies, advertising and promotion, Hatch-Waxman and orphan exclusivity issues, government investigations, and regulatory inspections and enforcement activities. She has been recognized as a leading life sciences lawyer by Chambers USA and earned accolades as a Law360 Rising Star and a Washington D.C. “40 under 40” lawyer.

Ms. Liu received her bachelor’s degree in government from Harvard University and her law degree from Columbia University.

What is Joy Liu's net worth?: The estimated net worth of Joy Liu is at least $3.82 million as of August 15th, 2022. Ms. Liu owns 9,605 shares of Vertex Pharmaceuticals stock worth more than $3,815,778 as of December 22nd. This net worth estimate does not reflect any other investments that Ms. Liu may own. Learn More about Joy Liu's net worth.
How do I contact Joy Liu?: The corporate mailing address for Ms. Liu and other Vertex Pharmaceuticals executives is 50 NORTHERN AVENUE, BOSTON MA, 02210. Vertex Pharmaceuticals can also be reached via phone at (617) 341-6100 and via email at [email protected]. Learn More on Joy Liu's contact information.
Has Joy Liu been buying or selling shares of Vertex Pharmaceuticals?: Joy Liu has not been actively trading shares of Vertex Pharmaceuticals during the last ninety days. Most recently, Joy Liu sold 3,747 shares of the business's stock in a transaction on Monday, August 15th. The shares were sold at an average price of $303.90, for a transaction totalling $1,138,713.30. Following the completion of the sale, the senior vice president now directly owns 9,605 shares of the company's stock, valued at $2,918,959.50. Learn More on Joy Liu's trading history.
Who are Vertex Pharmaceuticals' active insiders?: Vertex Pharmaceuticals' insider roster includes David Altshuler (EVP), Kristen Ambrose (CAO), Stuart Arbuckle (COO), E. Morrey Atkinson, III (EVP), Sangeeta Bhatia (Director), Jonathan Biller (EVP), Joshua Boger (Director), Carmen Bozic (CMO), Reshma FASN (M.D.), Reshma Kewalramani (CEO), Yuchun Lee (Director), Jeffrey Leiden (Chairman), Joy Liu (SVP), Margaret McGlynn (Director), Michael Parini (EVP), Amit Sachdev (EVP), Bruce Sachs (Director), Bastiano Sanna (EVP), Paul Silva (CAO), Ian Smith (COO), Ourania Tatsis (EVP), and Charles Wagner, Jr. (CFO). Learn More on Vertex Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Vertex Pharmaceuticals?: During the last year, insiders at the pharmaceutical company sold shares 23 times. They sold a total of 79,177 shares worth more than $36,823,476.56. The most recent insider tranaction occured on November, 15th when EVP David Altshuler sold 15 shares worth more than $7,178.40. Insiders at Vertex Pharmaceuticals own 0.2% of the company. Learn More about insider trades at Vertex Pharmaceuticals.
Information on this page was last updated on 11/15/2024.

Joy Liu Insider Trading History at Vertex Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/15/2022	Sell	3,747	$303.90	$1,138,713.30	9,605
8/9/2022	Sell	946	$300.00	$283,800.00	13,388
4/29/2022	Sell	120	$275.41	$33,049.20	14,334

Joy Liu Buying and Selling Activity at Vertex Pharmaceuticals

Vertex Pharmaceuticals Company Overview

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $397.27

$386.49

$401.31

50 Day Range

MA: $470.41

$396.64

$516.74

2 Week Range

Now: $397.27

$377.85

$519.88

Volume

6,202,268 shs

Average Volume

1,238,190 shs

Market Capitalization

$102.31 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.36

Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong

From Brownstone Research | Ad

Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.

Click here to watch this demo and decide for yourself.